Related Experiment Videos
Psychosis in Parkinson's disease
1Department of Neurology, University of Innsbruck, Innsbruck, Austria. werner.poewe@uibk.ac.at
Movement Disorders : Official Journal of the Movement Disorder Society
|September 23, 2003
Summary
Psychosis, particularly visual hallucinations, is a common complication in Parkinson's disease (PD). Managing PD psychosis involves addressing triggers, reducing medications, and considering antipsychotics or cholinesterase inhibitors.
Area of Science:
- Neurology
- Psychiatry
Background:
- Psychosis is a significant nonmotor complication in Parkinson's disease (PD).
- Visual hallucinations are the most frequent presentation, affecting up to 40% of advanced PD patients.
- Risk factors include age, cognitive impairment, depression, and disease severity/duration.
Purpose of the Study:
- To review the complexities of managing psychosis in Parkinson's disease.
- To highlight the role of antiparkinsonian drugs in inducing psychosis.
- To discuss treatment strategies for psychotic symptoms in PD patients.
Main Methods:
- Literature review of risk factors and management strategies for PD psychosis.
- Analysis of drug-induced psychosis, particularly with dopamine agonists.
- Evaluation of treatment options including polypharmacy reduction and atypical antipsychotics.
Main Results:
- Antiparkinsonian drugs can precipitate psychosis in at-risk individuals.
- Dopamine agonists are associated with early drug-induced psychosis (up to 16%) and later dementia risk.
- Management requires a multi-faceted approach, including medication adjustments and specific treatments.
Conclusions:
- Psychosis in PD is a complex challenge requiring careful management.
- Identifying and mitigating risk factors is crucial.
- Atypical antipsychotics and cholinesterase inhibitors offer therapeutic options for psychotic PD patients, especially those with dementia.